REMARKS

Claims 1-224 are pending in the application. In the Office Action of March 15, 2006, the Examiner has divided the claims into thirty one (31) groups:

Group I (claims 1-3) drawn to kit containing a peptide (MGFR) and candidate drug; Group II (claims 4-9) drawn to method of screening useful compound using peptide; Group III (claims 10-30) drawn to method of treatment using and agent whose structure is not recited in the claim but has the function of inhibiting interaction of an activating ligand with a portion of a cell surface receptor that interacts with the activating ligand to promote cell proliferation; Group IV (claims 31-40) drawn to method of treatment using an agent whose structure is not recited in the claim but has the function of preventing clustering of portions of cell surface receptors that interact with an activating ligand such as a growth factor to promote cell proliferation; Group V (claims 41-46, 63-67) drawn to kit comprising a species able to become immobilized relative to a shed cell surface receptor; Group VI (claim 47) drawn to a composition comprising at least a portion of a shed cell surface receptor interchain binding region and a signal entity; Group VII (claims 48-67) drawn to kit comprising a species characterized as 17kD-35, or derived from 14-3-3, which binds to various cell surface receptor in addition to a signaling entity; Group VIII (claims 68-85) drawn to peptide comprising at least a fragment of a sequence that corresponds to that portion of a cell surface reporter that interacts with an activating ligand and an affinity tag; Group IX (claims 86 and 87) drawn to kit comprising a particle, a fragment of MUC1; Group X (claims 88-106) drawn to kit comprising an article having a surface, a biomolecule, a second particle, a portion of cell surface molecule; Group XI (claim 107) drawn to method of exposing a ligand binding to a portion of a cell surface receptor; Group XII (claim 108) drawn to method of exposing portion of a cell surface receptor; Group XIII (claims 109-112) drawn to

method of exposing a synthetic drug; Group XIV (claims 113-118) drawn to method of treating by administering fusaric acid, L-alpha-methyl-dopa, calcimcycin; Group XV (claims 119-124) drawn to method of treating by administering etomoxir; Group XVI (claims 125-130) drawn to method of treating by administering L-alpha-methyl-dopa; Group XVII (claims 131-136) drawn to method of treating by administering calcimycin; Group XVIII (claims 137-142) drawn to method of treating by administering butylindazole; Group XIX (claims 143-148) drawn to method of treating by administering NS1619; Group XX (claim 149) drawn to method of exposing any one of the Markush group species, and determine disruption of the interaction; Group XXI (claim 150) drawn to method of treating by administering a compound without a structure identification; Group XXII (claims 151-157) drawn to method of treating with an agent that reduces cleavage of a cell surface receptor interchain binding region from the cell surface; Group XXIII (claims 158-184, 222 and 223) drawn to method of determining an amount of cleavage of a cell surface receptor; Group XXIV (claims 185-186) drawn to method of determining a cleavage site; Group XXV (claim 187) drawn to method of diagnosing a physiological state of cancer by determining a specific cleavage state of MUC1 distinguishable from a different cleavage state of MUC1; Group XXVI (claims 188-208 and 224) drawn to method of first and second amount of determining cleavage of cell surface receptor; Group XXVII (claims 209-217) drawn to method of diagnosing MUC1 positive breast, prostrate, lung, ovarian, colorectal, and/or brain cancer, and then treating; Group XXVIII (claim 218) drawn to method of treating using an agent for inhibiting interaction of an activating ligand unclassifiable due to the unidentified structure of the agent; Group XXIX (claim 219) drawn to method of treating using an agent for inhibiting dimerization of a portion of MUC1; Group XXX (claim 220) drawn to method of diagnosing MUC1 positive cancer by determining an amount of

cleavage of a MUC1 and; Group XXXI (claim 221) drawn to method of diagnosing, followed by treating using an agent for inhibiting dimerization of a portion of a MUC1.

Applicants traverse this requirement. Reconsideration and withdrawal thereof are earnestly requested.

The present invention is directed to a series of compositions, method, kits, articles and species associated primarily with the diagnosis and/or treatment of cell proliferation, specifically cancer. In particular, the present invention is directed to cell proliferation associated with aberrant expression of MUC1. Applicants submit that dividing the present invention into thirty one (31) different inventive groups is not proper since all of the inventive compositions, method, kits, articles and species are closely related to form a single invention. It would cause undue hardship on the Applicants to be forced to file individual applications for claims in each divided groups.

However, in order to be responsive to the outstanding Restriction Requirement, Applicants provisionally elect to prosecute Group I, claims 1-3, drawn to a kit containing a peptide (MGFR) and candidate drug, for prosecution on the merits, with traverse. Applicants specifically preserve the right to prosecute the non-elected claims.

Accordingly, early examination on the merits is respectfully requested.

The Commissioner is authorized to charge Deposit Account 502486 for any fees due to secure entry of this amendment to the extent necessary.

August 15, 2006

Respectfully submitted,

/Joseph Hyosuk Kim/
Joseph Hyosuk Kim, Ph. D.
Registration No. 41,425

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: 818-249-8177
Facsimile: 818-249-8277